You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ALX Oncology Holdings Inc. entered privately negotiated exchanges under which stockholders surrender 13,353,384 common shares for pre-funded warrants exercisable for the same number of shares at $0.001 per share; the Exchange will settle on or about October 15, 2026.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALXO
this stock
Alx Oncology Holdings Inc
|
$143.81M | -8.0% | — | — | 4.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
ALX Oncology Holdings Inc. entered privately negotiated exchanges under which stockholders surrender 13,353,384 common shares for pre-funded warrants exercisable for the same number of shares at $0.001 per share; the Exchange will settle on or about October 15, 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALXO | -10.0% | -1.9% | -46.1% | -14.8% | -8.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -12.6% | -0.7% | -46.6% | -14.6% | -18.6% |
